Next Science

Next Science CROIC

Delisted

The Cash Return on Invested Capital (CROIC) of Next Science (NXS.AX) as of Oct 29, 2026 is -144.09 %. In the previous year, Cash Return on Invested Capital (CROIC) was -115.67 % — a change of 24.56% (lower).

CROIC

-144.09 %

YoY

24.56%

Last updated:

Cash Return on Invested Capital (CROIC) of Next Science is 2024 -144.09 % . Cash Return on Invested Capital (CROIC) of Next Science was 2023 -115.67 % . It decreases by 24.56% lower compared to the previous year.

The Next Science CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2017
-81.46 USD
Jan 1, 2018
-177.25 USD
Jan 1, 2019
-70.24 USD
Jan 1, 2020
-65.59 USD
Jan 1, 2021
-81.33 USD
Jan 1, 2022
-132.52 USD
Jan 1, 2023
-115.67 USD
Jan 1, 2024
-144.09 USD
The Next Science CROIC history
YEARCROICYoY
-144.09 %+24.56%
-115.67 %-12.71%
-132.52 %+62.93%
-81.33 %+24.00%
-65.59 %-6.62%
-70.24 %-60.37%
-177.25 %+117.57%
-81.46 %-57.29%
-190.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Next Science stock

Cash Return on Invested Capital (CROIC) of Next Science is -144.09 % in 2024.

Cash Return on Invested Capital (CROIC) of Next Science changed from -115.67 % to -144.09 %, representing a 24.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Next Science since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Next Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Next Science

All Key Metrics — Next Science